Pharmala Biotech Holdings Inc.

Equities

MDMA

CA71719L1067

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 17:33:38 16/07/2024 BST			5-day change	1st Jan Change
0.11 ^CAD	0.00%		-8.33%	-21.43%

05-03	PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	MT
04-23	Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	CI

PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA

January 24, 2023 at 01:50 pm

PharmAla Biotech Holdings Inc. have received an export permit for 300 grams of its LaNeo™ MDMA. PharmAla believes this is the largest single Health Canada export permit ever granted by weight to date. The MDMA is destined for a client in the United Kingdom; the materials will be used in research and development, for a proposed commercial purpose.

Latest news about Pharmala Biotech Holdings Inc.

PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	05-03	MT
Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	04-23	CI
Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement	04-19	MT
Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding	04-18	CI
Pharmala Biotech Holdings Inc. announced that it expects to receive CAD 0.75 million in funding	04-09	CI
PharmAla Biotech Provides Australian Update	04-05	MT
US Patent and Trademark Office Grants Patent Allowance to Pharmala Biotech Holdings Inc. for ALA-002 Composition	03-27	CI
Pharmala Biotech Holdings Inc. Allowance Granted for Ala-002 Composition by US Patent and Trademark Office	03-27	CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness	03-26	MT
Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus	03-26	CI
PharmAla Says Patent Allowance Granted for P-1 Molecule by USPTO	03-20	MT
Pharmala Biotech Holdings Inc. Announces Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office	03-20	CI
PharmAla Biotech Holdings Inc. Announces Joint Venture with Cortexa Pty. Ltd	03-18	CI
PharmAla Named an Intellectual Property Ontario Client	02-22	MT
PharmAla Biotech Holdings Inc. Announces Data from its Computational Drug Discovery Program in the Scientific Journal ACS Chemical Neuroscience	02-20	CI
Listed Duo PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development	02-09	MT
PharmAla Biotech Holdings Inc. Enters into Consulting Relationship with Red Light Holland Corp	02-09	CI
PharmAla Reports Q1 Profit, Provides Business Update	01-31	MT
PharmAla up 41%, Granted Controlled Drugs & Substances Dealer's License by Health Canada	01-25	MT
PharmAla Biotech Holdings Inc. Receives A Controlled Drugs & Substances Dealer's License by Health Canada	01-25	CI
Pharmala Biotech Holdings Inc.'s PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance	01-08	CI
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules	11-15	MT
PharmAla Biotech Holdings Inc. Announces World's First Observational Trial to Assess Real-World Efficacy of MDMA Treatment	11-09	CI
PharmAla Biotech Received First Office Action for PharmAla-1 PCT Filing	25/09/23	MT
Pharmala Biotech Holdings Inc. Receives First Office Action for PharmAla-1 Pct Filing	25/09/23	CI

Chart Pharmala Biotech Holdings Inc.

Duration

Period

More charts

Company Profile

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

Sector

Biotechnology & Medical Research

Calendar

25/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMALA BIOTECH HOLDINGS INC.	-21.43%	7M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs